NASDAQ:KNSA

Kiniksa Pharmaceuticals . Class A Stock Insider Trading

Healthcare > Biotechnology

Buy KNSA

*Your capital is at risk

$47.85

+0.93 (+1.98%)

At Close: Jun 03, 2026

Kiniksa Pharmaceuticals . Class A Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -77.00. In total, the insiders bought 2.75M and sold 1.56M KNSA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-77.00
● Buy	2.75M shares
● Sell	1.56M shares
76% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 28, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -77. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 01, 2026 Buy	Class A Ordinary Share C-Conversion	Patel Sanj K Chairman & CEO	CEO / President	900 000 Value: $43.6M
Jun 01, 2026 Sell	Class B Ordinary Shares C-Conversion	Patel Sanj K Chairman & CEO	CEO / President	900 000 Value: $0
May 29, 2026 Buy	Restricted Share Units M-Exempt	Quart Barry D Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Restricted Share Units M-Exempt	Popovits Kimberly J Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Class A Ordinary Shares M-Exempt	Malley Thomas Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Share Option A-Award	Mccain Tracey L Director	Director	12 158 Value: $588.2K
May 29, 2026 Buy	Restricted Share Units A-Award	Levy Richard S Director	Director	2 026 Value: $98.0K
May 29, 2026 Buy	Class A Ordinary Share M-Exempt	Levy Richard S Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Restricted Share Units A-Award	Malley Thomas Director	Director	2 026 Value: $98.0K
May 29, 2026 Buy	Class A Ordinary Share M-Exempt	Cole G Bradley Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Non- Qualified Share Option (right to buy) A-Award	Baker Bros. Advisors Lp Director	Director	36 474 Value: $1.76M
May 29, 2026 Buy	Class A Ordinary Shares A-Award	Baker Bros. Advisors Lp Director	Director	6 078 Value: $294.1K
May 29, 2026 Buy	Restricted Share Units M-Exempt	Cole G Bradley Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Restricted Share Units A-Award	Cole G Bradley Director	Director	2 026 Value: $98.0K
May 29, 2026 Buy	Class A Ordinary Shares A-Award	Baker Bros. Advisors Lp Director	Director	6 078 Value: $294.1K
May 29, 2026 Buy	Restricted Share Units M-Exempt	Levy Richard S Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Share Option A-Award	Cole G Bradley Director	Director	12 158 Value: $588.2K
May 29, 2026 Buy	Restricted Share Units M-Exempt	Malley Thomas Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Share Option A-Award	Levy Richard S Director	Director	12 158 Value: $588.2K
May 29, 2026 Buy	Class A Ordinary Share M-Exempt	Mccain Tracey L Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Restricted Share Units A-Award	Mccain Tracey L Director	Director	2 026 Value: $98.0K
May 29, 2026 Buy	Share Option A-Award	Malley Thomas Director	Director	12 158 Value: $588.2K
May 29, 2026 Buy	Restricted Share Units A-Award	Popovits Kimberly J Director	Director	2 026 Value: $98.0K
May 29, 2026 Buy	Restricted Share Units A-Award	Quart Barry D Director	Director	2 026 Value: $98.0K
May 29, 2026 Buy	Class A Ordinary Share M-Exempt	Popovits Kimberly J Director	Director	2 799 Value: $135.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KINIKSA PHARMACEUTICALS LTD. CLASS A

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...

Read Full Profile Here